Hebei Changshan Biochem Pharma (300255) — Strategic Asset Allocation Index
Hebei Changshan Biochem Pharma (300255) has a Strategic Asset Allocation Index of 53.6% as of June 2023. Strategic assets (PP&E of CN¥1.55 Billion plus long-term investments of CN¥-) total CN¥1.55 Billion, measured against net assets of CN¥2.89 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See 300255 net asset quality score to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Hebei Changshan Biochem Pharma Strategic Asset Allocation Index (2008–2022)
This chart shows how Hebei Changshan Biochem Pharma's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of June 2023, the index stands at 53.6%, representing strategic assets of CN¥1.55 Billion against net assets of CN¥2.89 Billion CNY. For live market cap and overall valuation, see Hebei Changshan Biochem Pharma market capitalisation.
Annual Strategic Asset Allocation Index for Hebei Changshan Biochem Pharma (2008–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Hebei Changshan Biochem Pharma from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See 300255 total equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 48.6% | CN¥1.48 Billion | CN¥1.48 Billion | CN¥- | CN¥3.05 Billion | ▲ +9.8 pp |
| 2021 | 38.8% | CN¥1.19 Billion | CN¥1.19 Billion | CN¥- | CN¥3.07 Billion | ▲ +1.5 pp |
| 2020 | 37.3% | CN¥1.06 Billion | CN¥1.06 Billion | CN¥- | CN¥2.85 Billion | ▲ +2.9 pp |
| 2019 | 34.4% | CN¥935.32 Million | CN¥935.32 Million | CN¥- | CN¥2.72 Billion | ▲ +0.4 pp |
| 2018 | 34.0% | CN¥857.67 Million | CN¥849.48 Million | CN¥8.20 Million | CN¥2.52 Billion | ▲ +1.5 pp |
| 2017 | 32.5% | CN¥791.77 Million | CN¥769.51 Million | CN¥22.26 Million | CN¥2.44 Billion | ▲ +0.8 pp |
| 2016 | 31.8% | CN¥727.00 Million | CN¥662.45 Million | CN¥64.55 Million | CN¥2.29 Billion | ▼ -4.3 pp |
| 2015 | 36.0% | CN¥565.72 Million | CN¥565.72 Million | CN¥- | CN¥1.57 Billion | ▲ +1.0 pp |
| 2014 | 35.0% | CN¥499.33 Million | CN¥499.33 Million | CN¥- | CN¥1.43 Billion | ▲ +2.4 pp |
| 2013 | 32.6% | CN¥419.25 Million | CN¥419.25 Million | CN¥- | CN¥1.29 Billion | ▲ +8.0 pp |
| 2012 | 24.7% | CN¥277.63 Million | CN¥277.63 Million | CN¥- | CN¥1.13 Billion | ▲ +10.6 pp |
| 2011 | 14.0% | CN¥138.38 Million | CN¥138.38 Million | CN¥- | CN¥987.45 Million | ▼ -34.8 pp |
| 2010 | 48.8% | CN¥107.11 Million | CN¥107.11 Million | CN¥- | CN¥219.39 Million | ▲ +20.1 pp |
| 2009 | 28.7% | CN¥45.67 Million | CN¥45.67 Million | CN¥- | CN¥159.19 Million | ▼ -21.4 pp |
| 2008 | 50.0% | CN¥46.75 Million | CN¥46.75 Million | CN¥- | CN¥93.43 Million | — |